Related Experiment Video
Updated: Jul 16, 2026
05:24
Two Flow Cytometric Approaches of NKG2D Ligand Surface Detection to Distinguish Stem Cells from Bulk Subpopulations in Acute Myeloid Leukemia
Published on: February 21, 2021
CD52 expression in non-mycotic T- and NK/T-cell lymphomas
Sheng-Tsung Chang1, Chin-Li Lu, Shih-Sung Chuang
1Department of Pathology, Chi-Mei Medical Center, Tainan, Taiwan.
Leukemia & Lymphoma
|February 28, 2007
Summary
CD52 antigen expression was investigated in T-cell lymphoma (TCL) subtypes. Researchers found CD52 expression in 35% of eligible TCL cases, suggesting potential for alemtuzumab therapy.
Area of Science:
- Oncology
- Immunology
- Hematology
Background:
- CD52 antigen is highly expressed on lymphocytes and monocytes.
- Alemtuzumab (Campath-1H), a human anti-CD52 antibody, shows efficacy in T-cell malignancies.
- Limited data exists on CD52 expression in T-cell lymphoma (TCL) subtypes.
Purpose of the Study:
- To determine CD52 antigen expression rates across various T-cell lymphoma subtypes.
- To evaluate the potential utility of CD52 immunostaining in future alemtuzumab clinical trials for TCL.
Main Methods:
- Retrospective analysis of 97 T-cell lymphoma cases using immunohistochemistry on paraffin-embedded sections.
- Exclusion of 14 angioimmunoblastic T-cell lymphoma (AITL) cases due to difficulties in differentiating neoplastic T-cells from reactive B-cells.
- Analysis of CD52 expression in the remaining 83 TCL tumors.
Main Results:
- CD52 was expressed in 29 out of 83 (35%) evaluable TCL cases.
- Expression rates varied by subtype: 47% in NK/T-cell lymphomas, 40% in unspecified peripheral TCLs, and 22% in anaplastic large cell lymphomas.
- No significant association found between CD52 expression and patient age, gender, or disease presentation (nodal vs. extra-nodal).
Conclusions:
- CD52 antigen is expressed in a significant subset of T-cell lymphomas.
- CD52 immunostaining is recommended for future clinical trials involving alemtuzumab in TCL patients.
- Correlating CD52 expression levels with treatment outcomes is crucial for optimizing alemtuzumab therapy in TCL.
Related Concept Videos
01:22T Cell Activation and Clonal Selection
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
01:27Cytotoxic T Cells-mediated Immune Response
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...